Sahajanand Medical Technologies IPO
Sahajanand Medical Technologies IPO — date, price band, lot size & details 2026
Sahajanand Medical Technologies listed on 23 Oct 2026 at ₹371.15, 7.9% above the ₹344 issue price.
Sahajanand Medical Technologies makes Class III heart devices such as drug-eluting stents, TAVI valves and occluders. Total income was Rs 1,218.73 crore in FY2026 and restated profit after tax was Rs 69.08 crore.
Stock price
Sahajanand Medical Technologies is listed — here is the live share price.
Timetable
Key dates from opening to listing. Today is 17 November.
- Open 15 Oct 2026
- Close 19 Oct 2026
- Allotment 21 Oct 2026
- Refund/credit 22 Oct 2026
- Listing 23 Oct 2026
Latest news
Our news coverage of Sahajanand Medical Technologies, newest first.
Sahajanand Medical Technologies IPO Listing: NSE Open at ₹371.15, +7.89% on Issue Price
Sahajanand Medical Technologies IPO Lists on 23 October With a Grey Market Premium of ₹17
Sahajanand Medical Technologies IPO Closes 14.2x Subscribed, With QIBs at 34.7x
Sahajanand Medical Technologies IPO Opens 15 October at ₹327–344, All Offer for Sale
Issue summary
The terms of the offer, as filed.
| IPO Dates | 15 to 19 Oct, 2026 |
|---|---|
| Price Band | ₹327 – ₹344 |
| Face Value | ₹1 |
| Lot Size | 43 Shares |
| Issue Size | ₹475.48 Cr |
| Sale Type | OFS only |
| Listing On | BSE, NSE |
| Registrar | MUFG Intime India Private Limited |
| Min Investment | ₹ 14,792 |
Share of the offer set aside for each investor category, as stated in the offer document.
What will it cost me?
Bidding is in multiples of 43 shares at the ₹344 cut-off. Drag to size your application.
| Application | Lots | Shares | Amount |
|---|---|---|---|
| Retail (min) | 1 | 43 | ₹14,792 |
| Retail (max) | 13 | 559 | ₹1,92,296 |
| S-HNI (min) | 14 | 602 | ₹2,07,088 |
| S-HNI (max) | 67 | 2,881 | ₹9,91,064 |
| B-HNI (min) | 68 | 2,924 | ₹10,05,856 |
Strengths & risks
Drawn from the offer document — the case for and against, side by side.
Strengths · 6
- 01Total income grew from Rs 908.59 crore in FY2024 to Rs 1,035.96 crore in FY2025 and Rs 1,218.73 crore in FY2026.
- 02Profit after tax moved from a loss of Rs 7.35 crore in FY2024 to Rs 25.15 crore in FY2025 and Rs 69.08 crore in FY2026.
- 03EBITDA rose from Rs 110.05 crore in FY2024 to Rs 170.66 crore in FY2026, with an EBITDA margin of 13.81%.
- 04Net worth rose from Rs 526.30 crore in FY2024 to Rs 616.05 crore in FY2026, and Rs 631.72 crore on 30 June 2026.
- 05The company holds 102 granted patents and its products are backed by 72 clinical studies.
- 06Products are sold in over 76 countries, with direct operations in Germany, Spain, France and the UK.
Risks · 7
- 01The whole issue is an offer for sale of Rs 475.48 crore. The company receives no money from it, so none of the proceeds fund growth or reduce borrowing.
- 02At the upper band of Rs 344 the issue is priced at 57.91 times post issue EPS of Rs 5.94. One lot is 43 shares, about Rs 14,792 at the upper band.
- 03RoNW is 2.31% and RoCE is 3.16%, which are low for the size of the business, and FY2024 was a loss year.
- 04Total borrowing rose from Rs 175.27 crore in FY2024 to Rs 269.53 crore in FY2026 and Rs 320.63 crore on 30 June 2026.
- 05Promoter holding falls from 40.82% before the issue to 36.2% after it.
- 06The business depends on regulated Class III devices, so product approvals, clinical results and tenders can affect revenue.
- 07Sales are spread over many countries, so currency moves and local rules can affect results.
Three years of numbers
All figures in ₹ crore, as reported in the Sahajanand Medical Technologies offer document.
| Metric | 30 Jun 2026 | 31 Mar 2026 | 31 Mar 2025 | 31 Mar 2024 |
|---|---|---|---|---|
| Assets | 1,309.00 | 1,276.43 | 1,094.90 | 970.58 |
| Total Income | 354.33 | 1,218.73 | 1,035.96 | 908.59 |
| Profit After Tax | 15.09 | 69.08 | 25.15 | -7.35 |
| EBITDA | 48.58 | 170.66 | 128.02 | 110.05 |
| NET Worth | 631.72 | 616.05 | 545.23 | 526.30 |
| Reserves and Surplus | 706.86 | 692.48 | 580.71 | 556.57 |
| Total Borrowing | 320.63 | 269.53 | 224.96 | 175.27 |
See how this IPO compares — view listing performance of all mainboard IPOs.
Valuation & key ratios
Ratios are for the latest full financial year reported in the Sahajanand Medical Technologies RHP. EPS and P/E are post-issue — the table below carries the pre-issue comparison.
Sahajanand Medical Technologies IPO Valuation
How the issue prices the company before and after the fresh shares are created.
| Valuation Metric | Pre-Issue | Post-Issue |
|---|---|---|
| EPS (₹) | ₹6.80 | ₹5.94 |
| P/E Ratio (x) | 50.59 | 57.91 |
| Market Cap at Offer Price (₹ Cr) | ₹763.38 | ₹3,496.65 |
Pre-issue figures use the shareholding reported in the RHP; post-issue figures use the shareholding once the fresh issue has created new shares. The two differ because of that dilution and because post-issue earnings per share are often annualised, so the change can run in either direction. Market capitalisation is calculated at the ₹344 offer price. Compare the post-issue P/E against listed peers before deciding — a premium there is growth you are paying for in advance.
Where the money goes
How the company intends to use the proceeds of the issue.
Sahajanand Medical Technologies IPO Anchor Investors
10 anchor investors across 8 fund houses committed ₹140.06 Cr a day before the issue opened.
| Anchor Investor | Fund House | Shares | Amount (₹ Cr) | % of Anchor Book |
|---|---|---|---|---|
| Nippon India Small Cap Fund | Nippon India Mutual Fund | 1,145,090 | 39.39 | 28.12% |
| DSP Healthcare Fund | DSP Mutual Fund | 590,992 | 20.33 | 14.51% |
| Whiteoak Capital Flexi Cap Fund | Whiteoak Capital Mutual Fund | 184,341 | 6.34 | 4.53% |
| Whiteoak Capital Multi Asset Allocation Fund | Whiteoak Capital Mutual Fund | 87,204 | 3.00 | 2.14% |
| Whiteoak Capital Pharma & Healthcare Fund | Whiteoak Capital Mutual Fund | 145,340 | 5.00 | 3.57% |
| Invesco India Pharma & Healthcare Fund | Invesco Mutual Fund | 436,063 | 15.00 | 10.71% |
| UTI Healthcare Fund | UTI Mutual Fund | 436,063 | 15.00 | 10.71% |
| Allianz Global Investors Fund-Allianz India Equity | Allianz | 436,063 | 15.00 | 10.71% |
| Tata Aia Life Insurance Co.ltd.-Whole Life Aggressive Growth Fund-Ulif 010 04/01/07 Wla 110 | Tata Aia Life Insurance | 290,723 | 10.00 | 7.14% |
| Natixis International Funds (Lux) I-Loomis Sayles Global Emerging Markets Equity Fund | Natixis | 319,755 | 11.00 | 7.85% |
| Total anchor allocation | 140.06 | |||
Anchor investors bid a day before the issue opens and are locked in after allotment, so a book weighted towards domestic mutual funds is generally read as a stronger signal than one filled by short-horizon funds. Browse every anchor investor scheme or fund house we track.
About the company
The products fall in three groups. Vascular intervention covers coronary stents and balloons. Structural heart covers TAVI and occluders. Other products include renal stents, peripheral drug-coated balloons and some trading products.
The company has two R&D centres, one in India and one in Thailand, with 102 professionals. It holds 102 granted patents globally and has 71 pending applications. Key brands are Supraflex Cruz, Hydra (TAVI) and Cocoon (occluders), backed by 72 clinical studies and sold in over 76 countries. It sells directly in Germany, Spain, France and the UK, uses a hybrid model in India and distributors in markets such as Italy. As of 31 March 2025 it had 1,458 full-time staff, 24 consultants and 818 contract personnel.
Interested in this IPO? Check the live subscription status or browse all upcoming mainboard IPOs.
022 49564000
The bankers & the filings
Who is running the book, and the documents this page is built from.
Sahajanand Medical Technologies IPO Documents
Read the filings this page is built from.
Lead Manager Track Record
How the book-running lead managers on this issue have priced their past IPOs, measured on listing day.
HSBC Securities & Capital Markets (India) Pvt. Ltd.
34 issues handledBest listing: Gujarat State Petronet (+72.2%). Weakest: Nuvoco Vistas Corporation (-14.9%).
Nuvama Wealth Management Ltd.
42 issues handledBest listing: Gandhar Oil Refinery (India) (+76.3%). Weakest: ACME Solar Holdings (-13.1%).
Motilal Oswal Investment Advisors
79 issues handledBest listing: G R Infraprojects (+105.0%). Weakest: R K Swamy (-13.2%).
Avendus Capital
11 issues handledBest listing: FirstCry (+40.0%). Weakest: Innoventive Industries (-4.3%).
Listing gain compares the listing-day opening price with the issue price, using the IPOs on IPO Guru that this lead manager has taken to market. A strong record reflects how the banker has priced past issues — it is not a forecast for this one. See every issue they have handled on the lead managers page.
Company contact
Frequently asked
What is the GMP of Sahajanand Medical Technologies?
The current Grey Market Premium is ₹17, or 4.94% over the issue price.
What is the Sahajanand Medical Technologies IPO price band?
₹327 to ₹344, on a face value of ₹1.
When is the allotment?
The basis of allotment is 21 October 2026, with listing on 23 October 2026.
How do I check allotment status?
On the IPO Guru allotment page or on the registrar's site — MUFG Intime India Private Limited.
Every number here traces back to a filing.
IPO Guru tracks GMP, subscription and allotment for every Mainboard and SME issue. Every number on this page is sourced from the RHP, BSE & NSE.
Not investment advice. Grey market premium is an unofficial, unregulated indicator and is not a forecast.